Journal of Thyroid Disorders & Therapy
Open Access

Division of Surgery, Ito Hospital, Tokyo, Japan

Biography

Dr. Kiminori Sugino is a distinguished surgeon at Ito Hospital in Tokyo, Japan, specializing in thyroid and parathyroid diseases. His extensive research has significantly advanced the understanding and management of thyroid disorders, particularly Graves' disease and thyroid carcinomas. In 2012, Dr. Sugino co-authored a pivotal study titled "Changes in the Thyroid Function of Graves’ Disease Patients Treated by Subtotal Thyroidectomy," published in the Endocrine Journal. This research evaluated the outcomes of subtotal thyroidectomy in Graves' disease patients, providing valuable insights into postoperative thyroid function and influencing surgical approaches. Recognizing the need for improved surgical strategies, Dr. Sugino and his colleagues shifted from subtotal to total thyroidectomy for Graves' disease. Their findings, detailed in the 2019 study "Change of Surgical Strategy for Graves’ Disease from Subtotal Thyroidectomy to Total Thyroidectomy," demonstrated enhanced patient outcomes with total thyroidectomy, thereby impacting clinical practices. Dr. Sugino's research also extends to thyroid carcinomas. In 2020, he co-authored "Outcomes and Prognostic Factors of 251 Patients with Minimally Invasive Follicular Thyroid Carcinoma," published in Thyroid. This study identified key prognostic factors, aiding clinicians in tailoring treatment plans for affected patients. Furthering his contributions, Dr. Sugino co-authored a 2022 study titled "Impact of Age on Prognosis in Papillary Thyroid Carcinoma," which examined how age influences disease prognosis, providing critical data for risk stratification and management. In 2023, Dr. Sugino contributed to the research on "Clinical Features of Moyamoya Disease with Graves’ Disease," exploring the intersection of these conditions and offering insights into their concurrent management.

Publications

• Original Research Article   
  Factors Influencing the Chemo-Sensitivity of Weekly Paclitaxel for Anaplastic Thyroid Cancer: A Clinico-Pathologic Analysis of Cases Enrolled in a Clinical Trial
  Author(s): Naoyoshi Onoda*, Mitsuyoshi Hirokawa, Kennichi Kakudo, Atsuhiko Sakamoto, Kiminori Sugino, Noriaki Nakashima, Nobuyasu Suganuma, Shinichi Suzuki, Ken-ichi Ito and Iwao Sugitani
  
  This study was conducted to identify the clinico-pathologic factors influencing the response to weekly paclitaxel treatment for Anaplastic Thyroid Cancer (ATC), a rare refractory disease. We investigated clinico-pathological factors as well as the expressions of Ki67, p53, MAD2, TLE3, ALDH1, β-tubulin, E-cadherin and vimentin among the subjects enrolled in a recent nationwide clinical trial of 56 patients with ATC in Japan. We compared the factors of eight responders and eight non-responders. The responders survived significantly longer than the non-responders (median 11.6 vs. 3.6 months, p=0.039). No significant between-group difference was found in histological subtype, TNM classification, or the expression of Ki67, p53, MAD2, TLE3, ALDH1, β-tubulin, E-cadherin or vimentin. When the patients' Prognostic Index (PI) was determined with the sum of four clinical factors, i.. View More»
  

  Abstract PDF

Other relevant publications from this author

• Change of surgical strategy for Graves’ disease from subtotal thyroidectomy to total thyroidectomy: a single institutional experience

  ASO Author Reflections: Outcomes for Minimally Invasive Follicular Thyroid Carcinoma in AJCC 8th Edition

  Impact of Age on Prognosis in Papillary Thyroid Carcinoma: How Should Age be Incorporated into the Treatment Strategy?

  Clinical features of moyamoya disease with Graves’ disease: a retrospective study of 394,422 patients with thyroid disease